Clinical Pharmacology Cases
Waive Phase I to Enter Phase II/III via Ethnic Sensitivity Analysis
For modified-release formulations with approved counterparts overseas, a PBPK model is applied to predict systemic and local in vivo exposure of the new formulation. With ethnic sensitivity analysis, we support applications to waive Phase I trials and directly initiate Phase II/III clinical trials.
